The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: An evaluation of their measurement properties

Arthritis Care and Research

Volumn 53, Issue 2, 2005, Pages 256-262

  Johnson, Sindhu R ^a   Hawker, Gillian A ^a   Davis, Aileen M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

Disability; HAQ; HAQ DI; Health Assessment Questionnaire; Scleroderma; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEALTH CARE QUALITY; HUMAN; MEASUREMENT; PHYSICAL DISABILITY; PREDICTION AND FORECASTING; QUESTIONNAIRE; RELIABILITY; SCLERODERMA; SENSIBILITY; VALIDATION PROCESS; VISUAL ANALOG SCALE;

CLINICAL TRIALS; DISABILITY EVALUATION; HEALTH STATUS INDICATORS; HUMANS; MEDLINE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 17244368213     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21084     Document Type: Article

References (47)

1. Marx RG, Bombardier C, Hogg-Johnson S, Wright JG. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999;52:105-11.
2. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. Recombinant human relaxin in the treatment of scleroderma; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9.
3. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
4. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
5. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
6. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
7. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
8. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
9. Georges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3-10.
10. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003;30:1630-47.
11. Johnson SR, Lee P. The HAQ disability index in scleroderma trials. Rheumatology (Oxford) 2004;43:1200-1.
12. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 1985;38:27-36.
13. Wright JG, McLeod RS, Lossing A, Walters BC, Hu X. Measurement in surgical clinical research. Surgery 1996;119:241-4.
14. Feinstein AR. The theory and evaluation of sensibility. In: Clinimetrics. New Haven (CT): Yale University Press; 1987. p. 141-65.
15. Davis AM, Bell RS, Badley EM, Yoshida K, Williams JI. Evaluating functional outcome in patients with lower extremity sarcoma. Clin Orthop 1999;358:90-100.
16. Long AF, Dixon P. Monitoring outcomes in routine practice: defining appropriate measurement criteria. J Eval Clin Pract 1996;2:71-8.
17. Rineberg BA. A call to leadership: the role of orthopaedic surgeons in musculoskeletal outcomes research. J Bone Joint Surg Am 1990;72:1439-40.
18. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995;4:293-307.
19. Streiner DL, Norman GR. Validity. In: Health measurement scales: a practical guide to their development and use. Oxford (UK): Oxford University Press; 1995. p. 145-62.
20. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001;45:453-61.
21. De Bruin AF, Diederiks JP, de Witte LP, Stevens FC, Philipsen H. Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP68. J Clin Epidemiol 1997;50:529-40.
22. Meenan RF, Anderson JJ, Kazis LE, Egger MJ, Altz-Smith M, Samuelson CO Jr, et al. Outcome assessment in clinical trials: evidence for the sensitivity of a health status measure. Arthritis Rheum 1984;27:1344-52.
23. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Academic Press; 1988.
24. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27 Suppl:S178-89.
25. Fries JF, Hess EV, Klinenberg J. A standard database for rheumatic diseases. Arthritis Rheum 1974;17:327-36.
26. Convery FR, Minteer MA, Amiel D, Connett KL. Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 1977;58:494-9.
27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965;14:61-5.
28. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-9.
29. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
30. Smyth AE, MacGregor AJ, Mukerjee D, Brough GM, Black CM, Denton CP. A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford) 2003;42:732-8.
31. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
32. Moser DK, Clements PJ, Brecht ML, Weiner SR. Predictors of psychosocial adjustment in systemic sclerosis: the influence of formal education level, functional ability, hardiness, uncertainty, and social support. Arthritis Rheum 1993;36:1398-405.
33. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
34. Silman A, Akesson A, Newman J, Henriksson H, Sandquist G, Nihill M, et al. Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998;25:79-83.
35. Herrick A, Rooney B, Finn J, Silman A. Lack of relationship between functional ability and skin score in patients with systemic sclerosis. J Rheumatol 2001;28:292-5.
36. Ruof J, Bruhlmann P, Michel BA, Stucki G. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology (Oxford) 1999;38:535-42.
37. Guillevin L, Ortonne JP. Treatment of scleroderma. Ann Med Interne (Paris) 1983;134:754-65. In French.
38. Wright JG, Feinstein AR. Improving the reliability of orthopaedic measurements. J Bone Joint Surg Br 1992;74:287-91.
39. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
40. Poole JL, Williams CA, Bloch DA, Hollak B, Spitz P. Concurrent validity of the Health Assessment Questionnaire Disability Index in scleroderma. Arthritis Care Res 1995;8:189-93.
41. Patrick DL, Peach H, Gregg I. Disablement and care: a comparison of patient views and general practitioner knowledge. J R Coll Gen Pract 1982;32:429-34.
42. Calkins DR, Rubenstein LV, Cleary PD, Davies AR, Jette AM, Fink A, et al. Failure of physicians to recognize functional disability in ambulatory patients. Ann Intern Med 1991;114:451-4.
43. Brower LM, Poole JL. Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum 2004;51:805-9.
44. Sechrest L. Incremental validity: a recommendation. Educ Psychol Meas 1963;23:153-8.
45. Haynes SN, Lench HC. Incremental validity of new clinical assessment measures. Psychol Assess 2003;15:456-66.
46. Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
47. Sultan N, Pope JE, Clements PJ, Scleroderma Trials Study Group. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford) 2004;43:472-8.